{"id":"gc1107","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GC1107 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 receptors on T cells. This blockade restores T cell proliferation, activation, and anti-tumor cytotoxic function. The mechanism is similar to other PD-L1 inhibitors used in immuno-oncology.","oneSentence":"GC1107 is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from inhibiting T cell activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:47.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT02361866","phase":"PHASE3","title":"To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-05","conditions":"Bacterial Infections","enrollment":376},{"nctId":"NCT01402713","phase":"PHASE2, PHASE3","title":"To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2011-08","conditions":"Bacterial Infections","enrollment":311}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GC1107","genericName":"GC1107","companyName":"Green Cross Corporation","companyId":"green-cross-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"GC1107 is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from inhibiting T cell activation. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}